TY - JOUR
T1 - Impact of Trimetazidine Treatment on 5-year Clinical Outcomes in Patients with Significant Coronary Artery Spasm
T2 - A Propensity Score Matching Study
AU - Kim, Yong Hoon
AU - Her, Ae Young
AU - Rha, Seung Woon
AU - Choi, Byoung Geol
AU - Choi, Se Yeon
AU - Byun, Jae Kyeong
AU - Mashaly, Ahmed
AU - Park, Yoonjee
AU - Jang, Won Young
AU - Kim, Woohyeun
AU - Choi, Jah Yeon
AU - Park, Eun Jin
AU - Na, Jin Oh
AU - Choi, Cheol Ung
AU - Lim, Hong Euy
AU - Kim, Eung Ju
AU - Park, Chang Gyu
AU - Seo, Hong Seog
AU - Oh, Dong Joo
N1 - Publisher Copyright:
© 2017, Springer International Publishing AG.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Objective: We aimed to evaluate the additive benefit of trimetazidine with well-known antispasmodic agents such as calcium channel blockers and nitrate in patients with significant coronary artery spasm (CAS) as assessed by acetylcholine provocation test up to 5 years. Methods: A total 1727 patients with significant CAS were enrolled. They were divided into two groups: a trimetazidine group (trimetazidine, diltiazem, and nitrate, n = 695), and control group (diltiazem and nitrate, n = 473). After propensity score matching analysis, two matched groups (441 pairs, n = 882, C-statistic = 0.673) were generated. The individual and composite clinical end points [mortality, myocardial infarction (MI), revascularization, cerebrovascular accident (CVA), major adverse cardiac events (MACE), major adverse cardiac or cerebrovascular events (MACCE), and recurrent angina] were assessed up to 5 years for the two groups. Results: At 5 years, there were similar incidences of individual and composite hard endpoints including mortality, MI, revascularization, CVA, MACE, MACCE, and recurrent angina in the two groups. Conclusions: Additional long-term (5-year) treatment with trimetazidine in combination with diltiazem and nitrate in patients with significant CAS was not associated with improved clinical outcomes compared with combination therapy with diltiazem and nitrate only (without trimetazidine).
AB - Objective: We aimed to evaluate the additive benefit of trimetazidine with well-known antispasmodic agents such as calcium channel blockers and nitrate in patients with significant coronary artery spasm (CAS) as assessed by acetylcholine provocation test up to 5 years. Methods: A total 1727 patients with significant CAS were enrolled. They were divided into two groups: a trimetazidine group (trimetazidine, diltiazem, and nitrate, n = 695), and control group (diltiazem and nitrate, n = 473). After propensity score matching analysis, two matched groups (441 pairs, n = 882, C-statistic = 0.673) were generated. The individual and composite clinical end points [mortality, myocardial infarction (MI), revascularization, cerebrovascular accident (CVA), major adverse cardiac events (MACE), major adverse cardiac or cerebrovascular events (MACCE), and recurrent angina] were assessed up to 5 years for the two groups. Results: At 5 years, there were similar incidences of individual and composite hard endpoints including mortality, MI, revascularization, CVA, MACE, MACCE, and recurrent angina in the two groups. Conclusions: Additional long-term (5-year) treatment with trimetazidine in combination with diltiazem and nitrate in patients with significant CAS was not associated with improved clinical outcomes compared with combination therapy with diltiazem and nitrate only (without trimetazidine).
UR - https://www.scopus.com/pages/publications/85034065977
U2 - 10.1007/s40256-017-0254-z
DO - 10.1007/s40256-017-0254-z
M3 - Article
C2 - 29143297
AN - SCOPUS:85034065977
SN - 1175-3277
VL - 18
SP - 117
EP - 127
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 2
ER -